Lifecare

Carnegie Investment Bank congratulates Lifecare on the successful NOK 42.5 million private placement.
 
Lifecare is developing the next generation of miniaturized and implantable nanobiosensors for long-term use, with a particular focus on diabetes. Sencell, the company’s flagship sensor technology, provides real-time and accurate glucose readings by reading osmotic pressure and sending readings wirelessly to a smart device. Net proceeds will, among other things, be used for further research and clinical studies of Lifecare’s sensor technology, product development of the Sencell CGM system towards market launch in the veterinary market and CE mark preparations for the human market.
 
Carnegie is proud to have acted as sole bookrunner in the private placement, and wishes to thank CEO Joacim Holter and chairman Morten Foros Krohnstad for the vote of confidence.